Angelini Industries corporate venture fund joined Apollo Health Ventures, Sv health investors’ biotech fund, Dementia discovery fund, Dolby family ventures, Eli Lilly, Foundation for a better world, Mrl ventures fund, and Sanofi ventures.
After having recently closed a deal with Nuevocor (see here a previous post by BeBeez), Angelini ventures, the corporate venture capital of Angelini Industries for biotech and digital health investments, said it led the 39 million US Dollars extension of the Series A round (previous tranche worth 36 million) of Therini Bio, a California-based startup in clinical phase developing immunotherapies for neuroinflammation in vascular dysfunction diseases. The extension also attracted the resources of Apollo Health Ventures. Therini raised a total of 75 million from SV Health Investors’ Biotech Fund, Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures, and Foundation for a Better World (press release of TheriniBio and of Angelini Ventures).
Fabrizio Calisti, the medical director of Angelini Ventures, will join Therini Bio’s board of directors as auditor. The Californian company’s pioneering approach addresses the fundamental vascular dysfunction that contributes to neurodegenerative diseases. The company’s technology specifically targets inflammatory fibrin epitopes to halt the destructive cascade of neuroinflammation without compromising essential coagulation pathways.
Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio, said: “We are grateful to collaborate with such an important group of investors. Their support allows us to significantly advance our shared vision of offering patients a rational and innovative approach to potentially treating their debilitating conditions, including AD and DME.”
The company will invest the raised proceeds in the development of Fibrin-targeted immunotherapies for neurodegenerative diseases caused by vascular dysfunction. More specifically, the funding will enable Therini Bio to conduct advanced phase 1b studies evaluating THN391 for Alzheimer’s disease; continue clinical development for diabetic macular oedema applications; and support the development of a bispecific fibrin/VEGF therapy.
Thomas Thestrup, Ph.D., Senior Principal of Angelini Ventures and deal lead, added: “We are proud to support the mission of Therini Bio. As active investors in the CNS sector, we are excited about Therini’s first selective antibody therapy, which offers a revolutionary pathway to transform the treatment of diseases such as Alzheimer’s and age-related macular oedema (Dme)”.
In January 2025, Angelini Industries said it joined the 35 million euros Series B round of Belgium’s AgeTech (see here a previous post by BeBeez) and the 20 million Series A round of Danish Neumirna Therapeutics (see here a previous post by BeBeez). In March 2025, the firm invested in the 10 million Series A round of Germany’s Vantis (see here a previous post by BeBeez).
Angelini Ventures is born in 2022 and set a 300 million investments target (see here a previous post by BeBeez). The fund already poured resources in the region of 100 million in 19 targets such as Cour Pharmaceuticals, Noctrix Health, Nouscom, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience, Freya Biosciences, Nobi, and others.
Angelini Ventures is born in 2022 and set a 300 million investment target (see here a previous post by BeBeez). The fund already allocated 100 million in 19 companies such as Cour Pharmaceuticals, Noctrix Health, Nouscom, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience, Freya Biosciences, Neumirna Therapeutics, Nobi, Vantis, and others.
BeBeez Private Data, the private capital database of BeBeez and FSI, monitors Angelini Ventures and its Italian portfolio companies. Find out here how to subscribe for one month or one year or Click here for booking a demo videocall with BeBeez database manager
